弥合年龄差距:提升2型糖尿病与慢性肾脏病临床试验中老年人的代表性
本文指出慢性肾脏病在老年人群中常见,65岁以上者超过三分之一患有中重度CKD;但2型糖尿病与CKD临床试验持续低代表老年人,透析试验参与者比真实透析人群更年轻、更健康、死亡率更低,非透析依赖CKD试验的年龄差距更大。作者探讨代表性不足的障碍并提出改善未来试验纳入的策略。
要点
- 全球65岁以上人群中超过三分之一患有中重度慢性肾脏病(CKD)。
- 2型糖尿病(T2D)与CKD试验中老年人代表性持续偏低,非透析依赖CKD试验年龄差距更大。
- 代表性不足导致证据外推,可能造成T2D与CKD治疗不足或过度治疗。
核心结论
- 老年人被排除在试验之外,使社会承担可预防不良事件、不当用药及错失改善功能结局机会的代价。
- 解决试验人群与目标治疗人群之间的年龄差距,对确保老年人获得循证、公平的照护至关重要。
研究设计与样本
- 本文为Personal View(个人观点)文章,探讨老年人代表性不足的障碍并提出改善未来T2D与CKD试验纳入的策略。
主要发现
- 全球65岁以上人群中超过三分之一患有中重度CKD。
- 近期分析显示老年人T2D试验中代表性持续偏低。
- 透析试验参与者往往比真实世界透析人群更年轻、更健康、死亡率更低。
- 非透析依赖CKD试验报告的年龄差距更大。
- 证据基础受限使临床医生常需外推年轻人群结果或依赖观察性数据。
临床怎么用
- 临床医生在治疗老年人T2D与CKD时,常需外推年轻人群试验结果或依赖观察性数据。
- 应警惕因证据不足导致的T2D与CKD治疗不足或过度治疗。
局限性
- 本文为个人观点文章,未提供原始研究数据或系统检索范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is common among older adults, with more than a third of individuals older than 65 years having moderate to severe CKD globally. Management of CKD in older adults is often complex because of multiple comorbidities, polypharmacy, and frailty. However, older adults remain under-represented in clinical trials for both type 2 diabetes (T2D), which is the leading risk factor for CKD, and CKD itself. Recent analyses show consistent low representation of older adults in T2D trials. Similarly, participants of dialysis trials tend to be younger, healthier, and have a lower mortality rate than individuals in the real-world dialysis population, and even greater age disparities are reported in trials for non-dialysis-dependent CKD. This under-representation limits the evidence base for treating older adults and often compels clinicians to extrapolate findings from younger populations or rely on observational data. Consequently, both undertreatment and overtreatment of T2D and CKD might occur. Excluding older adults from trial participation leads to society bearing the costs of avoidable harms from preventable adverse events, inappropriate medication use, and missed opportunities to improve functional outcomes in an ageing population. Addressing this age gap in trial population and target treatment population is crucial to ensure evidence-based, equitable care for older adults. In this Personal View, we explore the barriers of under-representation of older adults and propose strategies to enhance their inclusion in future trials for T2D and CKD.
引用
- Yang C, Joosten H, Chepulis L, et al. Bridging the age gap: improving representation of older adults in clinical trials for type 2 diabetes and chronic kidney disease. Lancet Healthy Longev. 2025. PMID: 41290017. doi:10.1016/j.lanhl.2025.100796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。